Volume | 842,714 |
|
|||||
News | (1) | ||||||
Day High | 1.96 | Low High |
|||||
Day Low | 1.845 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ATAI Life Sciences NV | ATAI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.96 | 1.845 | 1.96 | 1.87 | 1.97 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,157 | 842,714 | $ 1.88 | $ 1,586,456 | - | 1.025 - 2.85 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:13:38 | formt | 219 | $ 1.93 | USD |
ATAI Life Sciences NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
310.44M | 166.01M | - | 314k | -40.22M | -0.24 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ATAI Life Sciences NV News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATAI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.18 | 2.20 | 1.80 | 1.92 | 1,136,143 | -0.25 | -11.47% |
1 Month | 1.80 | 2.85 | 1.68 | 2.28 | 2,519,832 | 0.13 | 7.22% |
3 Months | 1.80 | 2.85 | 1.58 | 2.08 | 1,707,807 | 0.13 | 7.22% |
6 Months | 1.24 | 2.85 | 1.025 | 1.84 | 1,420,649 | 0.69 | 55.65% |
1 Year | 2.13 | 2.85 | 1.025 | 1.81 | 1,093,962 | -0.20 | -9.39% |
3 Years | 21.00 | 22.91 | 1.025 | 3.97 | 976,617 | -19.07 | -90.81% |
5 Years | 2.38 | 22.91 | 1.025 | 3.92 | 857,763 | -0.45 | -18.91% |
ATAI Life Sciences NV Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |